gacyclidine (GK 11)

01/01/2001 - "Distribution of gacyclidine enantiomers after experimental spinal cord injury in rats: possible involvement of an active transport system."
11/01/2000 - "Efficacy of a new neuroprotective agent, gacyclidine, in a model of rat spinal cord injury."
05/01/2002 - "Obtaining reliable and specific pharmacological tools for those binding sites is of particular interest, since it is likely that they play a substantial role in the low neurotoxicity, and therefore tolerability, of gacyclidine, a new neuroprotective drug currently evaluated in clinical trials for the treatment of brain and spinal cord injuries."
08/25/2000 - "The aim of this study was to analyze the optimal time-window for neuroprotection by a novel NMDA antagonist, Gacyclidine, after experimental spinal cord injury, in terms of its functional, histopathological and electrophysiological effects. "
01/01/2001 - "The pharmacokinetics of gacyclidine enantiomers, a noncompetitive N-methyl-D-aspartate (NMDA) antagonist, were studied in plasma and spinal cord extracellular fluid (ECF) after experimental spinal cord injury in rats. "

06/01/2001 - "Beaufour-Ipsen is developing gacyclidine (GK-11) for the potential treatment of traumatic brain injury. "
01/01/2001 - "In traumatic brain injury models gacyclidine improves also behavioral parameters and neuronal survival. "
06/01/2004 - "The aim of this study was to assess the safety and efficacy of intravenous (IV) injections of gacyclidine, a novel NMDA receptor antagonist, for neurological and functional recovery following acute traumatic brain injury. "

05/01/2010 - "After constant perfusion of gacyclidine for 40-63 h, four out of six patients experienced a temporary relief from their tinnitus. "
05/01/2010 - "Gacyclidine might present a potent drug for the suppression of sensorineural tinnitus in humans and therefore should be considered for future double-blinded, placebo-controlled clinical trials. "
05/01/2010 - "Effects of extracochlear gacyclidine perfusion on tinnitus in humans: a case series."
05/01/2010 - "Thus, we thought that patients with therapy-resistant sensorineural tinnitus might benefit from a local therapy with gacyclidine. "
05/01/2010 - "Experiments in guinea pigs have shown that local administration of gacyclidine to the cochlea can suppress salicylate-induced tinnitus. "

08/01/1999 - "However, only gacyclidine is able to ensure complete management of nerve agent poisoning for rapid normalization of EEG activity, clinical recovery and neuroprotection. "
08/01/1999 - "Gacyclidine also ensures optimal management of severe nerve agent poisoning in animals neither pretreated nor receiving emergency therapy likewise during an unexpected exposure. "
03/01/1999 - "Acute soman poisoning in primates neither pretreated nor receiving immediate therapy: value of gacyclidine (GK-11) in delayed medical support."
01/01/2000 - "All of this reinforces the therapeutical value of gacyclidine, which is in the process of approval for human use in France for treatment of head injury, as a central nervous system protective agent for the treatment of OP poisoning."
03/01/1999 - "Overall, in the case of severe OP-poisoning, gacyclidine represents a promising adjuvant therapy to the currently available polymedication to ensure optimal management of organophosphate poisoning in man. "

01/01/2013 - "A low dose of GK11 improved the survival of the mice by 4.3% and partially preserved body weight. "